Category Archives: Emerging Markets

GSK Scores High in Market Access

By George Koroneos | Published: June 23, 2010
GlaxoSmithKline ranked number one in a study of pharmaceutical companies offering access to medicines to emerging and developing nations, proving that the UK drug giant has a far stronger grasp on new markets than its US and Japanese counterparts. The study ranks 20 companies based on significant criteria including pricing, patents and intellectual properties, capacity enhancement, [...]
Also posted in Strategy | Tagged , , , , , , , | Leave a comment

TB Alliance Trumpets New, Improved Drugs at World Health Assembly

By Oriana Schwindt | Published: May 19, 2010
Like polio and leprosy, developed countries have long since tamed tuberculosis. But even now, other parts of the world continue to struggle against the disease, with nearly all (98 percent) of TB’s 1.7 million worldwide deaths occurring in developing countries. TB’s high comorbidity with HIV infections has recently added another level of urgency to efforts [...]
Also posted in Corporate Responsibility, Global, R&D | Tagged , , , , , , , , , , | Leave a comment

US and Europe At Risk from Substandard Medicines

By Julian Upton | Published: February 25, 2010
Guest blog by Helen Disney, Chief Executive and Founder of the Stockholm Network, a pan-European think tank. When most of us look at taking a new medicine we tend to think it will make us better. Some of us may think about possible side effects but few of us expect the medicines we take to actually [...]
Also posted in Biotech, Europe, Global, Guest Blog, Regulatory, Safety | Tagged , , , , , , , , , , , | Leave a comment

Witty Proposes Price Cap for Poor Nations

By Cassandra Blohowiak | Published: February 18, 2009
GlaxoSmithKline CEO Andrew Witty proposed Friday to slash drug prices in the world’s 50 poorest countries and reinvest 20 percent of the profits in bolstering local health care. In a speech at Harvard Medical School Friday, Witty said drug prices will be capped at 25 percent of what they cost in developed nations. He also [...]
Also posted in Corporate Responsibility, People | Tagged , , , | Leave a comment

Gilead Making a Bundle

By Walter Armstrong | Published: February 10, 2009
Gilead Sciences has once again proven that independent biotechs can innovate with the best of Big Pharma. The Silicon Valley company’s wizardry at weaving multiple drugs into a single weft enabled it to overthrow GlaxoSmithKline as king of HIV in 2007. Yesterday, at the 16th annual Congress of Retroviruses and Opportunistic Infections (CROI), the biotech [...]
Also posted in Biotech, R&D | Tagged , , , | Leave a comment